Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 4,025,930 shares, a decline of 16.7% from the January 15th total of 4,830,166 shares. Currently, 5.7% of the company’s shares are short sold. Based on an average daily volume of 751,145 shares, the short-interest ratio is currently 5.4 days. Based on an average daily volume of 751,145 shares, the short-interest ratio is currently 5.4 days. Currently, 5.7% of the company’s shares are short sold.

Analysts Set New Price Targets

ZNTL has been the subject of a number of research reports. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target on shares of Zentalis Pharmaceuticals in a research report on Tuesday, November 11th. Finally, Morgan Stanley cut their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $4.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $5.00.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction on Friday, February 6th. The stock was sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the sale, the insider directly owned 156,779 shares in the company, valued at approximately $380,972.97. This represents a 16.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Matrix Capital Management Comp sold 7,500,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $1.33, for a total value of $9,975,000.00. Following the transaction, the insider directly owned 6,459,973 shares in the company, valued at $8,591,764.09. The trade was a 53.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 7,546,617 shares of company stock valued at $10,088,417 over the last quarter. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sivia Capital Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter worth $27,000. Catalyst Funds Management Pty Ltd purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter worth $31,000. Qube Research & Technologies Ltd acquired a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $37,000. Y Intercept Hong Kong Ltd purchased a new stake in Zentalis Pharmaceuticals in the second quarter valued at about $38,000. Finally, Corient Private Wealth LLC acquired a new stake in Zentalis Pharmaceuticals in the second quarter worth about $41,000.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock opened at $2.39 on Monday. The company has a market capitalization of $172.68 million, a PE ratio of -1.15 and a beta of 1.72. The company has a 50-day simple moving average of $2.18 and a two-hundred day simple moving average of $1.75. Zentalis Pharmaceuticals has a one year low of $1.01 and a one year high of $3.95.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.